STUDY GUIDE TEST 4

Direct Antiglobulin Test (DAT) Study Guide

1. Principle of the Antiglobulin Test

  • IgM antibodies:

    • Readily cause visible agglutination

  • IgG antibodies:

    • Do NOT cause agglutination on their own

How IgG is detected

  • Add anti-human globulin (AHG), which binds to the Fc portion of IgG

  • AHG is also called:

    • Coomb’s antibody

    • Coomb’s serum

    • “The green stuff”

What happens in the test

  • After centrifugation:

    • AHG forms a bridge between IgG-coated red blood cells

    • This creates visible agglutination

2. When is AHG Testing Used?

  • Antibody screening & identification

    • Detects antibodies against non-ABO antigens

    • Positive results require further testing before transfusion

  • Antigen typing

    • Determines if donor RBCs have certain antigens

    • Helps select compatible blood

  • Direct antiglobulin testing (DAT)

    • Detects in vivo coating of RBCs

    • Used when suspecting:

      • Hemolytic Disease of the Fetus and Newborn (HDFN)

      • Autoimmune Hemolytic Anemia (AIHA)

      • Hemolytic Transfusion Reaction (HTR)

3. Direct vs. Indirect Antiglobulin Test

Direct Antiglobulin Test (DAT)

  • Detects:

    • RBCs coated in vivo

  • Uses:

    • Patient RBCs

  • Purpose:

    • Determines if RBCs are already coated with IgG or complement

Indirect Antiglobulin Test (IAT)

  • Detects:

    • Antibodies in serum

  • Uses:

    • Patient serum + reagent RBCs

  • Purpose:

    • Detects unexpected antibodies

    • Determines antigen presence

Key Difference

  • DAT → In vivo coating

  • IAT → In vitro reaction

4. Direct Antiglobulin Test (DAT) Details

What DAT Detects

  • IgG coating

  • Complement (C3b, C3d)

  • Both IgG and complement

What DAT Does NOT Detect

  • IgM (unless complement activated)

  • IgA

Control

  • Patient RBCs + saline

  • If positive → suggests polyagglutination

5. Specimen Requirements

  • Use lavender top tube (EDTA)

    • EDTA chelates:

      • Calcium (Ca++)

      • Magnesium (Mg++)

  • Prevents complement activation in vitro

  • Ensures any complement detected occurred in vivo

6. DAT Procedure

Steps

  1. Start with polyspecific AHG reagent

  2. If positive:

    • Repeat using monospecific reagents

  3. Prepare fresh cell suspension

Important Step

  • If C3 test is negative:

    • Add complement-coated check cells

7. Interpretation of DAT Results

Positive DAT Indicates

  • RBCs are coated with antibody and/or complement

Associated Conditions

  • HDFN

    • Maternal antibodies coat fetal RBCs

  • HTR

    • Recipient antibodies coat donor RBCs

  • AIHA

    • Autoantibodies coat own RBCs

    • Types:

      • Warm

      • Cold

      • Paroxysmal Cold Hemoglobinuria (PCH)

  • Drug-induced hemolysis

8. Follow-Up to a Positive DAT

Clinical Evaluation

  • Diagnosis

  • Medications

  • Recent transfusions

Lab Values

  • Hematocrit & hemoglobin

  • Bilirubin

  • LDH

9. Elution

Definition

  • Process of removing antibodies from coated RBCs

How it Works

  • Breaks antigen-antibody bond

  • Releases antibody into solution (eluate)

Purpose

  • Identify antibody specificity

  • Test eluate against reagent RBC panels

10. Key Concepts to Remember

  • IgG needs AHG to agglutinate

  • DAT detects in vivo sensitization

  • EDTA prevents false complement activation

  • Positive DAT requires clinical follow-up

  • Elution helps identify the antibody causing the reaction

Hemolytic Disease of the Fetus & Newborn (HDFN) Study Guide

1. Definition & Characteristics of HDFN

  • HDFN is a condition where:

    • Fetal or neonatal RBCs have a shortened lifespan

    • Caused by maternal IgG antibodies binding to fetal RBCs

2. Pathophysiology of HDFN

Basic Mechanism

  • Maternal IgG crosses the placenta

  • IgG binds to fetal RBC antigens

  • Coated RBCs are destroyed by:

    • Macrophages in spleen and liver

  • Leads to extravascular hemolysis

Effects on the Fetus

  • Anemia

  • Increased RBC production by bone marrow

  • Release of NRBCs into circulation

  • Extramedullary hematopoiesis

  • Hepatosplenomegaly

  • Cardiac failure

Advanced Complications

  • Hypoproteinemia

  • Hydrops fetalis

  • Bilirubinemia

After Birth

  • Accumulation of unconjugated bilirubin

  • Due to immature liver

  • Causes:

    • Jaundice

    • Risk of kernicterus (brain toxicity)

3. Causes of HDFN

Requirements for HDFN to Occur

  1. Mother exposed to foreign antigen

  2. Mother produces antibody

  3. Antibody is IgG

  4. Fetus has the corresponding antigen

Exposure Sources

  • Previous pregnancy

  • Transfusion

Transplacental Hemorrhage Causes

  • Before delivery:

    • Abortion, ectopic pregnancy, amniocentesis, CVS

  • At delivery:

    • C-section, manual placenta removal, prolonged delivery

  • Other:

    • Trauma, transfusion

4. Antibodies Involved in HDFN

Most Severe

  • Anti-D

Most Common

  • Rh system: D, E, c

  • Kell

  • ABO

Less Common

  • Kidd

  • Duffy

  • Ss (rare)

5. Laboratory Role in HDFN

Maternal Testing

  • First visit:

    • ABO, Rh, antibody screen

  • If Rh negative:

    • Repeat screen at 28 weeks

  • If antibody present:

    • Antibody identification and titers

    • Monitor every 2–4 weeks

Paternal Testing

  • Determines fetal risk:

    • Homozygous → baby definitely has antigen

    • Heterozygous → 50% chance

    • Negative → no risk

Amniotic Testing

  • Detect:

    • Fetal antigens

    • Blood type

    • Bilirubin levels (hemolysis severity)

Cordocentesis (PUBS)

  • Umbilical blood sampling

Determines
  • Hemoglobin & hematocrit

  • Blood type

  • Antigen phenotype

  • DAT

Newborn Testing

  • Bilirubin

  • DAT

  • ABO/Rh typing

  • CBC

  • Hemoglobin & hematocrit

  • RBC morphology:

    • NRBCs

    • Polychromasia

    • Spherocytes

6. ABO vs Non-ABO HDFN

ABO HDFN

  • ~15% of pregnancies at risk

  • Usually:

    • Type O mother with A or B baby

  • Characteristics:

    • Mild severity

    • Can occur in first pregnancy

    • Appears 12–48 hours after birth

  • Treatment:

    • Phototherapy

Non-ABO HDFN

  • More severe

  • Usually not first pregnancy

  • Caused by:

    • Prior sensitization (pregnancy/transfusion)

  • Antigen inherited from father

  • Affects all future pregnancies with antigen-positive fetus

7. Rh (D) HDFN

Risk Situation

  • Mother: Rh negative

  • Father: Rh positive

  • Baby: may be Rh positive

What Happens

  • Mother exposed to D antigen

  • Produces Anti-D

  • Anti-D crosses placenta and destroys fetal RBCs

8. Rh Immune Globulin (RhIg)

What It Is

  • Injectable Anti-D IgG

How It Works

  • Binds fetal D+ cells in maternal circulation

  • Macrophages remove them

  • Prevents maternal immune response

  • Prevents formation of maternal Anti-D

Dosage

  • 300 µg:

    • Covers 15 mL packed RBCs (30 mL whole blood)

  • 50 µg (microdose):

    • Covers 2.5 mL packed RBCs

When RhIg is Given

  1. 26–28 weeks gestation

  2. Within 72 hours after delivery

  3. After:

    • Amniocentesis

    • PUBS

    • Abortion

    • Trauma

When RhIg is NOT Given

  • Mother is Rh positive

  • Mother already has Anti-D

  • Baby is Rh negative

Lab Complication

  • Passive Anti-D can cause:

    • Positive antibody screen up to 3 months

9. Neonate Testing

  • Cord blood tested for:

    • ABO typing

    • Rh typing (including weak D)

    • DAT

Important

  • Positive DAT:

    • Indicates antibody-coated RBCs

    • Invalidates weak D test

10. Elution

  • Removes antibodies from RBCs

  • Allows identification of antibody specificity

11. Tests for Fetomaternal Hemorrhage (FMH)

Rosette Test (Screening)

  • Detects D+ fetal cells in maternal blood

  • Interpretation:

    • ≥3 rosettes/5 fields → Positive

    • <3 → Negative

Kleihauer-Betke Test (Quantitative)

  • Based on:

    • Fetal cells contain HbF

    • Resistant to acid

  • Results:

    • Fetal cells = bright pink

    • Maternal cells = ghost-like

Calculation

  • % fetal cells × 50 = volume of FMH (mL)

  • FMH ÷ 30 = number of RhIg vials

  • Always add 1 vial

12. Treatment of HDFN

Phototherapy

  • Used for mild cases

  • UV light breaks down bilirubin

  • “Bili light” or “bili blanket”

Intrauterine Transfusion

  • For fetal anemia or hydrops

  • Blood given via umbilical vein

  • Goal:

    • Maintain Hb > 10 g/dL

  • Done every 2–4 weeks

Exchange Transfusion

  • After birth

  • Removes:

    • Bilirubin

    • Maternal antibodies

    • Coated RBCs

  • Replaces with donor blood

13. Key Concepts to Remember

  • HDFN requires IgG antibodies

  • Severity depends on antigen type

  • Anti-D is most severe

  • RhIg prevents sensitization

  • DAT confirms coated fetal RBCs

  • FMH testing determines RhIg dose

  • Treatments focus on:

    • Reducing bilirubin

    • Replacing RBCs

    • Preventing complications

Blood Donation Process Study Guide

1. Blood Product Manufacturing Process Flow

  • Blood is collected from donor

  • Samples drawn for testing

  • Blood sent to donor center

  • Processed into components:

    • Red blood cells

    • Platelets

    • Plasma

    • Cryoprecipitate

  • Labeled and stored

  • Released for transfusion after testing

2. Blood Usage & Supply Facts

  • Every 2 seconds someone in the U.S. needs blood

  • 41,000+ donations needed daily

  • 30 million components transfused yearly

  • One donation can help up to 3 people

  • Blood cannot be manufactured

  • Type O-negative:

    • Universal donor (RBCs)

    • High demand, short supply

  • AB plasma:

    • Universal plasma donor

  • Less than 10% of eligible people donate

3. Types of Blood Donations

Allogeneic Donation

  • Blood donated for use by others

Autologous Donation

  • Donor gives blood for self-use

  • Characteristics:

    • Can donate every 3 days (1 week recommended)

    • Minimum hematocrit: 33%

  • Advantages:

    • No antibody formation

    • No infectious disease transmission

    • Increased patient confidence

  • Limitation:

    • Can only be used for that patient

Directed Donation

  • Donor gives blood for a specific person

  • Not necessarily safer

  • Must meet all donor requirements

  • Special considerations:

    • Must be irradiated if from relative (risk of GVHD)

    • Mothers discouraged donating to children

    • Husbands discouraged donating to wives (risk of HDFN)

4. Apheresis Process

  • Blood collected via machine

  • Machine separates components

  • Specific components collected:

    • Platelets

    • Plasma

    • Red cells

  • Remaining blood returned to donor

  • Takes longer than whole blood donation

5. Donation Frequency Limits

  • Whole blood (RBCs):

    • Every 56 days

  • Double RBCs:

    • Every 112 days

  • Platelets:

    • Every 7 days

    • Max 24 times/year

  • Autologous:

    • Every 3 days (recommended weekly)

6. Donor Eligibility Requirements

General Requirements

  • Good health

  • Feeling well

  • Minimum age:

    • 17 years old

    • 16 with parental consent (allowed in Arkansas)

  • Minimum weight:

    • 110 lbs

Hemoglobin Requirement

  • Minimum:

    • 12.5 g/dL

  • Most common reason for deferral:

    • Low hemoglobin/hematocrit

Additional Factors

  • Travel history

  • Health history

  • Vital signs checked:

    • Temperature

    • Pulse

    • Blood pressure

7. Four Steps of Blood Donation Process

Step 1: Registration

  • Sign-in process

  • Review eligibility

  • Show ID

  • Read donation information

Step 2: Health History & Mini-Physical

  • Confidential interview:

    • Health history

    • Travel history

  • Mini-physical includes:

    • Temperature

    • Pulse

    • Blood pressure

    • Hemoglobin

Step 3: Donation (Phlebotomy)

Procedure
  • Arm cleaned

  • Sterile needle inserted

  • Blood collected (~1 pint)

Timing
  • Donation: 8–10 minutes

  • Entire visit: ~1 hour 15 minutes

Collection Details
  • First 30–40 mL diverted

    • Used for testing or discarded

  • Multiple tubes collected for testing

  • Blood bag system:

    • 4 connected bags

    • Contains anticoagulant

Step 4: Refreshments

  • Rest 10–15 minutes

  • Eat and drink

  • Resume normal activities

  • Recovery:

    • Plasma: 24 hours

    • RBCs: weeks

8. Blood Components & Storage

Components

  • Red blood cells

  • Platelets

  • Plasma

  • Cryoprecipitate

Shelf Life

  • RBCs: 42 days

  • Platelets: 5 days

  • Plasma/cryo: up to 1 year (frozen)

9. Laboratory Testing on Donated Blood

All Units Tested For

  • HIV 1 & 2

  • Hepatitis B

  • Hepatitis C

  • Syphilis

  • HTLV-I/II

  • West Nile Virus

  • Trypanosoma cruzi

  • Babesia

  • CMV

  • COVID

10. Whole Blood Donation Labeling

  • Unique donor number

  • Blood product type

  • Anticoagulant used

  • Volunteer donor statement

  • Blood type and expiration added after testing

11. Special Donation Types

Double Red Cell Donation

  • Higher requirements:

    • Males:

      • ≥5’1”, ≥130 lbs

    • Females:

      • ≥5’5”, ≥150 lbs

Intra-Operative Autologous Collection

  • “Cell saver”

  • Blood collected during surgery

  • Reinfused to patient

  • Must be used within 24 hours

12. Key Concepts to Remember

  • Blood donation is a safe, sterile process

  • One donation can save up to 3 lives

  • Apheresis allows targeted component collection

  • Strict eligibility and testing ensure safety

  • Blood has limited shelf life, especially platelets

  • Donation frequency depends on component type

  • Testing prevents infectious disease transmission

Blood Component Preparation Study Guide

1. Overview of Blood Components

  • Whole blood is separated into:

    • Red blood cells (RBCs)

    • Plasma

    • Platelets

  • From one donation → 3 main components produced

2. Blood Collection & Initial Preparation

Collection System

  • 4-bag system connected by tubing

  • ~500 cc whole blood collected

  • Mixed with 70 mL CPD

CPD Components

  • Citrate → anticoagulant

  • Phosphate → buffer, supports ATP production

  • Dextrose → nutrient

3. Component Separation Process

Primary Separation (Soft Spin)

  • Separates:

    • RBCs

    • Platelet-rich plasma (PRP)

Secondary Separation (Hard Spin)

  • PRP separated into:

    • Platelets

    • Plasma

4. Red Blood Cells (RBCs)

Preparation

  • PRP removed

  • Add additive solution

  • Store at 1–6°C

RBCs in CPD

  • Volume: 200–250 mL

  • Hematocrit: 75–85%

  • Expiration: 21 days

RBCs with Additive Solution

  • Volume: 300–350 mL

  • Hematocrit: 55–60%

  • Expiration: 42 days

Additive Solution Contains

  • Adenine → ATP production

  • Saline + dextrose → nutrients

  • Mannitol → membrane stability

  • Citrate compounds

Clinical Use

  • Increase oxygen-carrying capacity

  • Used for:

    • Blood loss >25%

    • Anemia (Hct <26%)

  • 1 unit RBC → ↑ Hct by ~3%

5. RBC Storage & “Storage Lesion”

Changes During Storage

  • ↓ Glucose

  • ↓ pH

  • ↓ ATP

  • ↓ 2,3-DPG

  • ↓ Sodium

  • ↑ Potassium

  • Slight ↑ hemolysis

Glycolytic Pathway Impact

  • Glucose consumed → acid produced

  • Acid ↓ 2,3-DPG

  • ↓ 2,3-DPG → impaired O₂ delivery

  • ↓ ATP → shortened RBC lifespan

Key Point

  • ATP level = main factor in RBC effectiveness

  • 2,3-DPG restored 24 hrs after transfusion

6. Special Types of RBCs

Fresh RBCs (<5 days old)

Used for:

  • Intrauterine transfusions

  • Neonates (<4 months)

  • Pediatric surgeries

  • Sickle cell patients

Leukoreduced RBCs

  • WBCs removed via filtration

Benefits:

  • ↓ cytokines

  • ↓ CMV transmission

  • ↓ febrile transfusion reactions

  • ↓ immune sensitization

Indications:

  • Organ transplant patients

  • Chronically transfused patients

  • Prior febrile reactions

  • Cardiac surgery patients

Irradiated RBCs

  • Exposed to 25 Gy radiation

  • Prevents T-cell proliferation

Purpose:

  • Prevent graft-versus-host disease (GVHD)

Indications:

  • Immunocompromised patients

  • Bone marrow/stem cell transplant

  • Intrauterine transfusions

  • Leukemia/blood cancers

  • AIDS

  • Blood from relatives

  • HLA-matched products

7. Platelets

Random Donor Platelets (RDP)

  • Stored at 20–24°C

  • Kept in constant motion

  • Given in pools (4–6 units; standard = 4)

Effect

  • ↑ platelet count by 25,000–50,000

Compatibility

ABO
  • Platelets have few ABO antigens

  • Plasma contains antibodies

  • Prefer ABO-compatible plasma

Rh
  • Platelets have no Rh antigens

  • RBC contamination may cause sensitization

  • Give Rh-negative platelets to:

    • Rh-negative females of childbearing age

Apheresis Platelets

  • From single donor

  • Equivalent to 4–5 random donors

Advantages:

  • ↓ alloimmunization

  • ↓ infection risk

  • Can be HLA matched

Storage

  • Same as RDP:

    • 5 days

    • Room temp with agitation

8. Platelet Bacterial Contamination

Risk

  • ~0.1–0.2% contaminated

  • Common organisms:

    • Skin flora

Prevention (Donor Center)

  • Skin cleansing

  • First 30–50 mL diverted

Detection (Transfusion Center)

  • Culture (standard)

  • pH & glucose testing

  • PCR (most effective)

9. Plasma

Fresh Frozen Plasma (FFP)

  • Contains all clotting factors

  • Frozen within 8 hours

Storage

  • Frozen: -18°C (1 year)

  • Thawed: 1–6°C (24 hours)

24-Hour Plasma

  • Frozen within 24 hrs (not 8 hrs)

  • Slightly ↓ factors V & VIII

  • Used interchangeably with FFP

Thawed Plasma

  • If not used in 24 hrs:

    • Relabeled

  • Can be used up to 5 days

  • Deficient in factors V & VIII

Special Note

  • Male plasma preferred:

    • Avoid HLA antibodies from pregnancy

10. Cryoprecipitate

Contents

  • Factor VIII (≥80 IU)

  • Fibrinogen (≥150 mg)

  • von Willebrand factor

  • Factor XIII

Uses

  • DIC

  • Hemophilia A

  • Fibrin glue

Preparation

  • Made from FFP

  • Thawed at 4°C

  • Refrozen at -18°C

Storage

  • Frozen: 1 year

  • Thawed:

    • 20–24°C

    • 6 hours (4 hours if pooled in lab)

Administration

  • Small volume: 10–20 mL

  • Usually pooled (≈10 units)

Pre-pooled Product Advantages

  • Faster availability

  • Less labor

  • Longer post-thaw time

11. Key Concepts to Remember

  • Whole blood → separated into RBCs, plasma, platelets

  • Soft spin vs hard spin determines separation

  • RBC storage leads to biochemical changes (storage lesion)

  • ATP and 2,3-DPG are critical for RBC function

  • Platelets require room temp + agitation

  • Plasma must be frozen quickly to preserve factors

  • Cryoprecipitate is factor-rich concentrate

  • Special RBC products prevent:

    • Infection

    • Immune reactions

    • GVHD

Transfusion Reactions Study Guide

1. Overview of Transfusion Reactions

Definition

  • An undesirable result of a blood transfusion

  • Often caused by an immune (antigen-antibody) reaction

  • Antibodies may target:

    • Red cells

    • White cells

    • Platelets

    • Plasma proteins

Key Concept

  • Transfusions are inherently risky

  • Cannot always be predicted or prevented

  • Must:

    • Weigh risks vs benefits

    • Obtain informed consent

    • Only transfuse when necessary

2. Categories of Transfusion Reactions

Hemolytic

  • Acute Hemolytic Transfusion Reaction (AHTR)

  • Delayed Hemolytic Transfusion Reaction (DHTR)

Non-Hemolytic

  • Allergic

  • Febrile non-hemolytic

  • Anaphylactic

  • TRALI

  • TACO

  • GVHD

3. General Clinical Symptoms

Mild–Moderate

  • Fever, chills

  • BP changes

  • Dyspnea

  • Urticaria (hives)

  • Nausea/vomiting

  • Wheezing

  • Pain (infusion site, back)

  • Red urine

  • Anxiety

Severe

  • Renal failure

  • Respiratory arrest

  • Cardiac arrest

  • Shock

  • DIC

  • Death

HEMOLYTIC TRANSFUSION REACTIONS

4. Acute Hemolytic Transfusion Reaction (AHTR)

Cause

  • ABO incompatibility

  • Usually due to human error

Pathophysiology

  • Recipient antibodies react with donor RBCs

  • Activates complement cascade

  • Leads to intravascular hemolysis

Onset

  • Minutes to hours

Symptoms

  • Fever (most common)

  • Chills

  • Back/flank pain

  • Hypotension

  • Dyspnea

  • Hemoglobinuria

  • “Feeling of doom”

  • Severe → shock, DIC, renal failure

Key Facts

  • Can occur with as little as 10 mL incompatible blood

  • Severity depends on amount transfused

Treatment

  • Immediate recognition

  • Maintain blood pressure

  • Correct coagulopathy

  • Maintain urine flow

5. Delayed Hemolytic Transfusion Reaction (DHTR)

Cause

  • Secondary immune response

  • Antibody previously formed but undetectable

Pathophysiology

  • Antigen-positive donor cells transfused

  • Antibody production increases

  • Extravascular hemolysis (liver/spleen)

Onset

  • Days to weeks

Symptoms

  • Fever

  • Anemia

  • Jaundice

  • No rise in hematocrit

Lab Findings

  • ↓ Hematocrit

  • ↑ Bilirubin

  • ↑ LDH

  • Blood smear:

    • Spherocytes

    • Reticulocytes

  • DAT:

    • Positive or negative

  • Antibody screen:

    • May be positive or negative

Treatment

  • Monitor patient

  • Correct anemia

  • Future transfusions:

    • Use antigen-negative blood

NON-HEMOLYTIC TRANSFUSION REACTIONS

6. Allergic Reactions

Cause

  • Hypersensitivity to plasma proteins

Pathophysiology

  • IgE-mediated

  • Mast cell degranulation → histamine release

Onset

  • Seconds to minutes

Symptoms

  • Urticaria

  • Watery eyes

  • Runny nose

  • Angioedema

Treatment

  • Stop transfusion temporarily

  • Give Benadryl

  • Resume if symptoms resolve

Prevention

  • Premedication (Benadryl)

7. Anaphylactic Reaction

Cause

  • Often IgA deficiency with anti-IgA antibodies

Pathophysiology

  • Severe IgE-mediated reaction

Symptoms

  • Airway swelling

  • Hypotension

  • Shock

  • Rapid weak pulse

Treatment

  • Stop transfusion immediately

  • Maintain airway & oxygenation

Prevention

  • Autologous blood

  • Washed RBCs/platelets

  • IgA-deficient donor plasma

8. Febrile Non-Hemolytic Reaction (FNHTR)

Definition

  • Temperature rise >1°C

Cause

  • Antibodies to WBC antigens

  • Cytokine release

Symptoms

  • Fever

  • Chills

  • Anxiety

  • BP changes

Treatment

  • Stop transfusion

  • Give acetaminophen

Prevention

  • Leukoreduction

  • Premedication

9. TRALI (Transfusion-Related Acute Lung Injury)

Cause

  • Donor antibodies to recipient WBCs

Pathophysiology

  • Immune complexes damage lung capillaries

  • ↑ permeability → pulmonary edema

Onset

  • 1–2 hours post-transfusion

Symptoms

  • Dyspnea

  • Cyanosis

  • Hypotension

  • Pulmonary edema

  • Fever

Treatment

  • Oxygen

  • Ventilation support

Prevention

  • Male-only plasma policy

10. TACO (Transfusion-Associated Circulatory Overload)

Cause

  • Fluid overload (non-immune)

Pathophysiology

  • Heart cannot handle increased volume

  • Leads to CHF and pulmonary edema

Symptoms

  • Dyspnea

  • Hypertension

  • Tachycardia

  • Edema

  • Rales

Treatment

  • Stop transfusion

  • Oxygen

  • Diuretics

  • Sit patient upright

At-Risk Patients

  • Elderly

  • Infants

  • Cardiac patients

11. Transfusion-Associated GVHD

Cause

  • Donor T-cells attack recipient

Requirements

  1. HLA differences

  2. Donor immune cells present

  3. Recipient cannot reject them

Onset

  • 8–10 days

Symptoms

  • Rash

  • Fever

  • Enterocolitis

  • Liver dysfunction

  • Pancytopenia

Outcome

  • >90% mortality

Prevention

  • Irradiated blood products

  • Leukoreduction is NOT sufficient

12. Other Complications

  • Transfusion-related sepsis

  • Massive transfusion complications:

    • Citrate toxicity

    • Electrolyte imbalances

    • Coagulopathy

    • Hypothermia

  • Platelet refractoriness

  • Post-transfusion purpura

  • Iron overload

13. Clinical Evaluation (Nursing Role)

Steps

  1. Stop transfusion

  2. Treat symptoms

  3. Notify physician & blood bank

  4. Collect:

    • EDTA blood sample

    • Urine sample

  5. Send:

    • Blood bag & tubing

    • Documentation

  6. Recheck vitals

14. Laboratory Evaluation

Basic Work-Up (ALL reactions)

Purpose

  • Detect hemolytic reactions

Steps

  • Clerical check

  • Visual hemolysis check

  • DAT

  • Repeat ABO typing

  • Urine hemoglobin

Clerical Check

  • Correct patient?

  • Correct blood unit?

Visual Hemolysis

  • Pink/red → acute hemolysis

  • Yellow → delayed hemolysis

DAT

  • Detect coated RBCs

  • Look for mixed-field reactions

15. If Basic Work-Up is Negative

  • No further testing

  • Wait for pathologist approval

16. If Basic Work-Up is Positive

Extended Work-Up

  • Repeat ABO/Rh

  • Repeat antibody screen

  • Repeat crossmatch

If DAT Positive

  • Perform elution

Elution Interpretation

  • All cells negative → drug effect/non-specific

  • All cells positive → autoantibody/high-incidence antigen

  • A or B cells only → ABO antibody

  • Panel pattern → alloantibody

Additional Testing

  • Culture donor unit

  • Test for:

    • HLA antibodies

    • Anti-IgA

  • Hemolysis labs:

    • ↓ Haptoglobin

    • ↑ Bilirubin

    • ↑ LDH

    • ↑ Reticulocytes

    • Spherocytes

17. Key Concepts to Remember

  • AHTR = ABO mismatch = intravascular hemolysis

  • DHTR = delayed IgG response = extravascular hemolysis

  • Most reactions are non-hemolytic

  • Always:

    • Stop transfusion first

    • Perform basic work-up

  • DAT + elution = key diagnostic tools

  • Prevention focuses on:

    • Proper identification

    • Leukoreduction

    • Irradiation

    • Careful monitoring

Study Guide: QC & Regulations in Transfusion Medicine

Objective 1: FDA’s Five Layers of Safety

The FDA ensures blood safety through five key layers:

1. Donor Screening

  • Evaluation before donation

  • Identifies risk factors (medical history, behaviors)

  • Prevents unsafe individuals from donating

2. Blood Testing

  • Each unit is tested for:

    • Infectious diseases

    • Blood type compatibility

  • Ensures safety of collected blood

3. Deferred Donor Lists

  • Records individuals who are not eligible to donate

  • Prevents future donations from unsafe donors

4. Quarantine

  • Blood units are held until:

    • Testing is completed

    • Safety is confirmed

  • Prevents release of unsafe blood

5. Recognition and Reporting of Problems

  • Identification of:

    • Errors

    • Deficiencies

    • Adverse events

  • Reporting to regulatory agencies is required

Objective 2: Federal Regulations and Risk Management

Regulatory Authority

  • Based on:

    • Public Health Service Act

    • Federal Food, Drug, and Cosmetic Act

  • Blood is classified as a biological product

  • Oversight by Center for Biologics Evaluation and Research (CBER)

Manufacturing Blood Products

Includes:

  • Collection

  • Processing

  • Testing

  • Distribution

Must follow:

  • Current Good Manufacturing Practices (cGMP)

Regulations Dissemination

  • Published in the Federal Register

  • Guidance documents:

    • Level 1: new or controversial regulations

    • Level 2: minor changes to existing regulations

Registration and Licensing

  • Facilities must:

    • Register with the FDA

    • List products they manufacture

  • Applies to:

    • Blood collection centers

    • Hospital blood banks

    • Testing labs

    • Storage/distribution centers

  • License required for interstate distribution

Inspections

  • Conducted:

    • Before licensing

    • Every 2 years after

  • Evaluate:

    • Quality assurance

    • Donor eligibility system

    • Testing system

    • Quarantine/inventory management

    • Processing systems

  • Additional inspections may occur from other agencies

Violations

Possible FDA actions:

  • Warning letter

  • License suspension or revocation

  • Legal action (injunction, seizure, prosecution)

Adverse Event Reporting

Must report to CBER:

  • Transfusion-related fatalities

  • Donation-related deaths

Medicolegal Aspects of Transfusion Medicine

Definition

  • Legal consequences of transfusion-related injury or death

Common Legal Issues

  • ABO errors

  • TRALI

  • Patient privacy violations

  • Transfusion-transmitted disease

  • Lack of informed consent

Torts

  • Improper interactions leading to harm:

    • Battery

    • Negligence

    • Liability

    • Emotional distress

    • Invasion of privacy

Risk Management Strategies

Donor-related

  • Pre-donation screening

  • Testing of donor units

Patient safety

  • Notify recipients if unsafe blood was given

  • Proper labeling and distribution

Clinical practice

  • Informed consent

  • Documentation of testing

  • Appropriate transfusion indications

  • Prevention of physician negligence

Ethical Principles

  • Autonomy: patient decision-making

  • Beneficence: act in patient’s best interest

  • Justice: fair and equal treatment

Objective 3: Compliance vs Quality Management

Quality Management (QM)

  • Continuous process

  • Focuses on maintaining and improving quality

  • Keeps facility inspection-ready

Compliance

  • Correction of identified deficiencies

  • Measured during inspections

  • Represents a single point in time

Key Distinction

  • Compliance alone does not ensure quality

  • QM is ongoing and proactive

Objective 4: 12 Quality System Essentials (QSEs)

1. Organization

  • Defines structure and relationships

  • Includes:

    • Medical director responsibilities

    • Communication pathways

    • Emergency preparation

2. Customer Focus

Customers include:

  • Patients

  • Physicians/nurses

  • Donors

Focus is on meeting their needs

3. Personnel

Defines:

  • Qualifications

  • Training

  • Competency testing

  • Continuing education

4. Equipment

Covers:

  • Selection and validation

  • Use and monitoring

  • Maintenance and calibration

  • Record keeping

5. Purchasing and Inventory

Ensures:

  • Supplier qualification

  • Vendor selection

  • Inspection of incoming materials

  • Ongoing evaluation

6. Process Management

Most comprehensive QSE

Ensures:

  • Controlled procedures

  • Quality of blood and components

Includes:

  • Quality control

  • Sterility

  • Identification and traceability

  • Storage and handling

  • Labeling

  • Testing

  • Timeliness

Requires adherence to cGMP

7. Documents and Records

Principle:

  • If it is not documented, it was not done

Includes:

  • Control and format

  • Review and updates

  • Proper use

  • Retention

8. Information Management

  • Management of patient and donor data

  • Ensures:

    • Confidentiality

    • Data integrity

9. Nonconformance Management

Handles:

  • Errors

  • Adverse events

  • Transfusion reactions

  • Transfusion-transmitted diseases

Requires:

  • Identification

  • Documentation

  • Reporting to FDA when necessary

10. Assessments

Internal

  • Routine audits

  • Monitoring trends

External

  • Inspections by FDA, AABB, CAP, TJC, CMS

Requires correction of deficiencies

11. Continual Improvement

Focus:

  • Prevent future problems

Methods:

  • Error tracking

  • Data analysis

  • PDCA cycle (Plan, Do, Check, Act)

12. Facilities and Safety

Ensures:

  • Safe work environment

Includes:

  • Environmental controls

  • Fire and electrical safety

  • Infection control

  • Biohazard disposal

  • Disaster preparedness

Requires staff training and documentation

Quality Concepts

Quality Control (QC)

  • Detects process failures during routine operations

Quality Assurance (QA)

  • Planned actions to ensure systems function properly

Quality Systems (QS)

  • Comprehensive framework integrating QC and QA

Key Points for Review

  • FDA safety relies on five layers working together

  • CBER oversees blood safety

  • cGMP is essential for process control

  • Legal risk arises from errors, lack of documentation, and poor consent

  • Quality management is continuous; compliance is periodic

  • Know all 12 QSEs, especially process management